| Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Shoemaker Daniel D | Chief Scientific Officer | Jan 11 | Sale | 110.81 | 3,253 | 360,477 | 83,609 | Jan 12 08:38 PM | | TAHL CINDY | General Counsel and Secretary | Jan 11 | Sale | 110.81 | 3,254 | 360,587 | 90,035 | Jan 12 08:39 PM | | Valamehr Bahram | Chief Development Officer | Jan 11 | Sale | 110.81 | 3,254 | 360,588 | 77,727 | Jan 12 08:40 PM | | Wolchko J Scott | President and CEO | Jan 11 | Sale | 110.81 | 8,587 | 951,556 | 350,562 | Jan 12 08:41 PM | | Redmile Group, LLC | Director | Jan 08 | Buy | 85.50 | 327,485 | 27,999,968 | 12,957,222 | Jan 12 04:16 PM | | Wolchko J Scott | President and CEO | Jan 08 | Sale | 117.10 | 60,820 | 7,122,217 | 359,149 | Jan 12 08:41 PM | | Valamehr Bahram | Chief Development Officer | Jan 08 | Sale | 117.10 | 6,230 | 729,552 | 80,981 | Jan 12 08:40 PM | | TAHL CINDY | General Counsel and Secretary | Jan 08 | Sale | 117.10 | 6,229 | 729,434 | 93,289 | Jan 12 08:39 PM | | Shoemaker Daniel D | Chief Scientific Officer | Jan 08 | Sale | 117.10 | 6,229 | 729,434 | 86,862 | Jan 12 08:38 PM | | Wolchko J Scott | President and CEO | Dec 17 | Option Exercise | 6.62 | 20,000 | 132,400 | 439,969 | Dec 18 04:01 PM | | Wolchko J Scott | President and CEO | Dec 17 | Sale | 91.82 | 20,000 | 1,836,352 | 419,969 | Dec 18 04:01 PM | | Valamehr Bahram | Chief Development Officer | Dec 14 | Option Exercise | 2.90 | 25,000 | 72,500 | 112,211 | Dec 15 04:01 PM | | Valamehr Bahram | Chief Development Officer | Dec 14 | Sale | 97.78 | 25,000 | 2,444,477 | 87,211 | Dec 15 04:01 PM | | Shoemaker Daniel D | Chief Scientific Officer | Nov 16 | Sale | 51.83 | 25,000 | 1,295,746 | 93,091 | Nov 16 05:12 PM | | Wolchko J Scott | President and CEO | Nov 13 | Option Exercise | 5.73 | 30,000 | 172,008 | 430,123 | Nov 16 04:02 PM | | Wolchko J Scott | President and CEO | Nov 13 | Sale | 51.03 | 30,000 | 1,530,900 | 419,969 | Nov 16 04:02 PM | | Wolchko J Scott | President and CEO | Nov 12 | Option Exercise | 2.73 | 30,000 | 81,900 | 449,969 | Nov 16 04:02 PM | | Wolchko J Scott | President and CEO | Nov 12 | Sale | 52.72 | 30,000 | 1,581,524 | 419,969 | Nov 16 04:02 PM | | TAHL CINDY | General Counsel and Secretary | Nov 05 | Option Exercise | 2.82 | 19,282 | 54,340 | 118,800 | Nov 06 04:02 PM | | TAHL CINDY | General Counsel and Secretary | Nov 05 | Sale | 50.63 | 19,282 | 976,252 | 99,518 | Nov 06 04:02 PM | | TAHL CINDY | General Counsel and Secretary | Nov 04 | Option Exercise | 2.73 | 51,519 | 140,647 | 151,037 | Nov 06 04:02 PM | | TAHL CINDY | General Counsel and Secretary | Nov 04 | Sale | 50.41 | 51,519 | 2,597,140 | 99,518 | Nov 06 04:02 PM | | TAHL CINDY | General Counsel and Secretary | Oct 16 | Option Exercise | 2.73 | 29,199 | 79,713 | 128,717 | Oct 20 04:01 PM | | TAHL CINDY | General Counsel and Secretary | Oct 16 | Sale | 50.25 | 29,199 | 1,467,212 | 99,518 | Oct 20 04:01 PM | | TAHL CINDY | General Counsel and Secretary | Oct 01 | Option Exercise | 2.73 | 35,000 | 95,550 | 134,518 | Oct 02 04:01 PM | | TAHL CINDY | General Counsel and Secretary | Oct 01 | Sale | 40.74 | 35,000 | 1,426,065 | 99,518 | Oct 02 04:01 PM | | Valamehr Bahram | Chief Development Officer | Sep 14 | Option Exercise | 2.75 | 25,000 | 68,778 | 112,211 | Sep 16 04:02 PM | | Shoemaker Daniel D | Chief Scientific Officer | Sep 14 | Sale | 36.30 | 25,000 | 907,540 | 118,091 | Sep 16 04:01 PM | | Valamehr Bahram | Chief Development Officer | Sep 14 | Sale | 36.28 | 25,000 | 907,024 | 87,211 | Sep 16 04:02 PM | | Redmile Group, LLC | Director | Jun 11 | Buy | 28.31 | 1,412,928 | 39,999,992 | 12,629,737 | Jun 17 08:25 PM | | RASTETTER WILLIAM H | Director | Mar 30 | Option Exercise | 1.37 | 28,461 | 38,992 | 28,461 | Mar 31 04:01 PM | | Valamehr Bahram | Chief Development Officer | Feb 03 | Option Exercise | 1.69 | 1,153 | 1,949 | 87,211 | Feb 04 04:01 PM | | Wolchko J Scott | President and CEO | Jan 30 | Option Exercise | 2.70 | 25,000 | 67,500 | 444,969 | Feb 03 04:01 PM | | Wolchko J Scott | President and CEO | Jan 30 | Sale | 25.45 | 25,000 | 636,303 | 419,969 | Feb 03 04:01 PM |
|
